Incyte Corp (INCY) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Incyte Corp (INCY) stock forecast summary
Our AI ranks Incyte Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Incyte Corp is a large-cap company with a market capitalization of $21.70B. It ranks number 2 by market capitalization among the 12 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its Net Margin of 26.7% is the highest of the 11 peers that report one.
A per-ticker accuracy statistic for INCY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, INCY included.
Follow INCY freeINCY price chart and AI forecast
How INCY ranks among 5379 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Incyte Corp (INCY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | INCY | Rank |
|---|---|---|
| Market Cap | $21.70B | 2/12 |
| P/E Ratio | 17.49x | – |
| P/B Ratio | 4.45x | 5/8 |
| EPS | $7.08 | – |
| Book Value/Share | $24.40 | – |
| Revenue/Share | $26.83 | – |
Profitability & Margins
| Metric | INCY | Rank |
|---|---|---|
| ROE | 25.5% | 2/10 |
| ROA | 19.5% | 2/13 |
| ROIC | 27.5% | 4/12 |
| Gross Margin | 92.5% | 1/7 |
| Operating Margin | 30.1% | 1/13 |
| Net Margin | 26.7% | 1/11 |
| EBT Margin | 33.1% | 1/13 |
| Tax Rate | 19.3% | – |
Financial Health
| Metric | INCY | Rank |
|---|---|---|
| Current Ratio | 3.68x | 4/16 |
| Quick Ratio | 3.60x | 3/6 |
| D/E Ratio | 0.31x | 8/11 |
| Financial Leverage | 1.31x | 8/11 |
| Interest Coverage | 213.7x | 2/13 |
| Working Capital | $3.99B | 1/15 |
Cash Flow
| Metric | INCY | Rank |
|---|---|---|
| Operating Cash Flow | $1.52B | 2/15 |
| OCF Growth YoY | 296.4% | 1/5 |
Operational Efficiency
| Metric | INCY | Rank |
|---|---|---|
| Asset Turnover | 0.73x | 4/9 |
| Receivables Turnover | 5.1x | 5/7 |
| Inventory Turnover | 3.5x | – |
| Fixed Assets Turnover | 7.4x | 4/9 |
| Days Sales Outstanding | 72 days | 3/7 |
| Days Inventory | 105 days | – |
| Payables Period | 207 days | 2/6 |
| Cash Conversion Cycle | -31 days | – |
Income Statement
| Metric | INCY | Rank |
|---|---|---|
| Total Revenue | $5.36B | 2/8 |
| Operating Income | $1.61B | 2/15 |
| Net Income | $1.43B | 1/13 |
| R&D Expense | $2.13B | 1/7 |
| SG&A Expense | $1.38B | 2/12 |
| Cost of Goods Sold | $403M | 3/8 |
Dividend & Shareholder Information
| Metric | INCY | Rank |
|---|---|---|
| Shares Outstanding | 200M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $5.48B | 74.7% of assets |
| Cash & Short-term Investments | $3.46B | 47.2% of assets |
| Accounts Receivable | $1.05B | 14.3% of assets |
| Inventory | $116M | 1.6% of assets |
| Total Liabilities | $1.72B | 23.4% of assets |
| Short-term Debt | $1.26B | 17.2% of assets |
INCY quarterly financials and insider trading
Incyte Corp (INCY) industry peers
Companies classified under the same SEC industry code as Incyte Corp (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| INCY Incyte Corp | ▼ | $21.70B |
| IQV Iqvia Holdings Inc. | ▼ | $43.51B |
| MEDP Medpace Holdings, Inc. | ▶ | $17.02B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.27B |
| ICLR Icon Plc | ▶ | $12.68B |
| ABSI Absci Corp | ▲ | $1.56B |
| OABI Omniab, Inc. | ▲ | $683M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $100M |
| ONMD Onemednet Corp | ▶ | $23M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BUDZ Weed, Inc. | ▶ | $3M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | N/A |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
| FOXO Foxo Technologies Inc. | ▼ | N/A |
| ISPC Ispecimen Inc. | ▼ | N/A |
Where INCY sits on the market map
Incyte Corp (INCY) stock news
Loading...
Incyte Corp (INCY) stock forecast FAQ
What is the Incyte Corp (INCY) stock forecast?
Our AI ranks Incyte Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Incyte Corp stock predictions?
A per-ticker accuracy statistic for INCY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Incyte Corp forecasts updated?
Incyte Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Incyte Corp's industry peers?
16 issuers in our coverage, INCY included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI), Omniab, Inc. (OABI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.